Combining L-NAME with Cancer Treatments
Author Information
Author(s): de Wilt J H W, Manusama E R, van Etten B, van Tiel S T, Jorna A S, Seynhaeve A L B, ten Hagen T L M
Primary Institution: Department of Surgical Oncology, University Hospital Rotterdam/Daniel den Hoed Cancer Centre
Hypothesis
Inhibition of nitric oxide synthase by L-NAME can enhance anti-tumour effects when combined with melphalan and TNF in isolated limb perfusions.
Conclusion
L-NAME significantly reduces tumour growth and enhances the effectiveness of melphalan and TNF in treating solid tumours.
Supporting Evidence
- Systemic treatment with L-NAME significantly inhibited growth of adenocarcinoma.
- In isolated limb perfusion, L-NAME alone reduced tumour growth.
- L-NAME increased response rates significantly when combined with TNF or melphalan.
Takeaway
This study shows that a substance called L-NAME can help make cancer treatments work better by stopping blood flow to the tumours.
Methodology
The study used a renal subcapsular adenocarcinoma model in rats and an isolated limb perfusion model to test the effects of L-NAME.
Limitations
The systemic treatment with L-NAME impaired renal function.
Participant Demographics
Rats were used in the study.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website